Framework rationale and scope
This framework presents a structured approach to quality control for preclinical efficacy studies, designed for laboratories, sponsor teams, and contract partners such as a preclinical CRO. It defines what must be tested, why each test matters, and where failures most commonly occur. The logic is systematic: define objectives, enumerate verification points, assign responsibility, and close loops before data lock.
Foundational principles
Start from three unambiguous objectives: internal validity (does the study measure the intended effect?), external reproducibility (can another lab reproduce the effect?), and regulatory traceability (are records complete for review?). Tests map directly to these objectives. Each control must be measurable, time-stamped, and tied to a standard operating procedure.
Design verification tests
Confirm study design fidelity before animals are dosed. Key tests: randomisation logs (sequence, block sizes), blinding confirmation (who was blinded and how), power calculations and assumptions, and control selection justification. Verify that inclusion/exclusion criteria are pre-specified and locked; any deviation requires documented amendment and independent review.
Assay and endpoint validation
Validate all analytical assays and functional readouts with specific tests: accuracy, precision, linearity, limit of detection, and matrix effects for biochemical assays; inter- and intra-assay reproducibility for imaging and behavioural endpoints. For composite endpoints, test each component separately and the composite algorithm together. Maintain calibration records for instruments and reagent lot tracing for antibodies and kits.
Pharmacokinetic/pharmacodynamic (PK/PD) concordance
Measure exposure at relevant time points and correlate to pharmacodynamic markers. Tests required: sample stability under handling conditions, assay validation for PK matrices, time-matched PD sampling, and exposure–response analyses. Flag discordant patterns for immediate root-cause analysis before proceeding to efficacy conclusions.
Animal model and welfare checks
Verify strain, health status, and source authentication. Tests include pathogen screening where applicable, genotyping confirmation for transgenic models, and baseline phenotype assessment. Record and audit environmental parameters (temperature, humidity, light cycle) that influence phenotype expression. Welfare observations must be coded, timestamped, and reconciled with endpoint data to prevent confounding.
Data integrity and electronic records
Confirm audit trails on electronic lab notebooks and instrument software: immutable timestamps, user IDs, and signed data flows. Run integrity checks for raw data completeness, file hashes, and metadata consistency. Implement batch reconciliation for sample IDs between bench records and the central database to prevent mislabelled samples from skewing outcomes.
Statistical plan verification and sample-size audits
Lock a statistical analysis plan (SAP) prior to unblinding. Tests should verify that the SAP matches the protocol and that interim analyses follow pre-specified rules. Conduct a blinded sample-size re-estimation only if pre-defined criteria allow it. When outsourcing analysis, require independent code review and reproducibility checks of primary endpoints.
Operational checkpoints and chain of custody
Test the integrity of sample handling: chain-of-custody forms, temperature log validation for cold-chain samples, and aliquot traceability. For tissue-based endpoints, confirm fixation protocols and processing times do not vary beyond validated windows. Cross-check labelling at each transfer point; automated scans reduce human error and must be audited.
Common pitfalls and corrective testing
Frequent failures arise from inadequate blinding, underpowered designs, and poor assay transfer. Corrective tests include replicate assays with independent operators, blinded re-analysis by a second statistician, and verification runs with reference controls. Document root-cause analyses and implement targeted retraining when human error is implicated.
EEAT: experience, expertise, authoritativeness and trustworthiness
Teams should demonstrate practical experience and peer-reviewed competence. Independent verification—such as presenting methods and results at the Drug Information Association (DIA) Global Annual Meeting—provides a public, verifiable anchor for method credibility. Where statistical analysis is outsourced, require documented expertise in regulatory-grade methods; many groups now contract explicit biostatistics CRO services for SAP drafting, code review, and reproducible reporting to satisfy both scientific and regulatory expectations.
Implementation checklist
Adopt a concise checklist tied to the study timeline: protocol lock and SAP sign-off; assay validation completion; randomisation and blinding verification; PK/PD sample plan validated; chain-of-custody forms ready; interim checkpoints scheduled; final data integrity audit planned. Assign specific owners for each item and require sign-off evidence before milestone gating.
Synthesis and practical value
Applying this framework yields fewer re-runs, clearer regulatory dialogues, and reliable decisions about candidate progression. Quality control is not a single test but an orchestrated set of verifications that protect study validity; when teams follow structured checkpoints and independent statistical review, results become defensible and actionable, as demonstrated in multiple industry case studies that align with the procedures used by KCI Biotech.
